No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.

Details

This publication is an old version. This notice is replaced by serval:BIB_4A53A3D43CC0
Ressource 1 Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_683DA0C4D026
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Journal
BMC research notes
Author(s)
Claude F., Rochat I., Hafen G.M.
ISSN
1756-0500 (Electronic)
ISSN-L
1756-0500
Publication state
Published
Issued date
04/03/2019
Peer-reviewed
Oui
Volume
12
Number
1
Pages
115
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months' period.
Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
Keywords
Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/pharmacology, Child, Ciprofloxacin/administration & dosage, Ciprofloxacin/pharmacology, Clinical Protocols, Cystic Fibrosis/complications, Female, Humans, Male, Outcome and Process Assessment (Health Care), Pseudomonas Infections/drug therapy, Pseudomonas Infections/etiology, Pseudomonas aeruginosa/drug effects, Retrospective Studies, Time Factors, Tobramycin/administration & dosage, Tobramycin/pharmacology, Cystic fibrosis, Eradication protocol, Primoinfection, Pseudomonas aeruginosa
Pubmed
Open Access
Yes
Create date
07/04/2019 15:10
Last modification date
30/10/2023 9:57
Usage data